Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Analysis of integrated radiographic data from two long-term, open-label extension studies of adalimumab for the treatment of rheumatoid arthritis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Sex Differences in the Achievement of Remission and Low Disease Activity in Rheumatoid Arthritis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Growth and puberty in juvenile dermatomyositis: a longitudinal cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Antinuclear Antibody-Negative Systemic Lupus Erythematosus in an International Inception Cohort

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Robert Landewé
  • Mikkel Østergaard
  • Edward C Keystone
  • Stefan Florentinus
  • Shufang Liu
  • Désirée van der Heijde
Vis graf over relationer

OBJECTIVE: A longitudinal integration approach evaluated all radiographic scores assessed over 10 years, rather than only completer data, from 2 studies of adalimumab (ADA) for rheumatoid arthritis (RA).

METHODS: The DE019 (methotrexate [MTX]-inadequate responders, longstanding RA) and PREMIER (MTX-naive, early RA) studies, respectively, had 1- or 2-year double-blind periods followed by 9- or 8-year open-label extensions (OLEs). Patients received ADA ± MTX in both OLEs. Radiographic progression was assessed using change from baseline in modified total Sharp score (ΔmTSS). A mixed-effects model was used post hoc to evaluate repeated measurements of different data campaigns and to estimate ΔmTSS through up to 10 years of treatment based on original randomization groups (placebo [PBO] + MTX or standard dose ADA + MTX).

RESULTS: Data from patients with baseline and ≥1 postbaseline radiograph were included (n = 327 for DE019; n = 452 for PREMIER). Integrated and 10-year completer ΔmTSS progression curves differed slightly. In DE019, for patients originally assigned PBO + MTX, accrued ΔmTSS at year 10 was 6.6 units (integrated model) and 6.2 units (completers). For patients originally assigned ADA + MTX, accrued ΔmTSS was 0.9 units by integrated analysis and 0.7 units in completers. In PREMIER, for patients originally assigned PBO + MTX, accrued ΔmTSS at year 10 was 11.2 units (integrated analysis) and 11.0 units (completers). For patients originally assigned ADA + MTX, accrued ΔmTSS was 5.1 units (integrated analysis) and 4.0 units (completers). A higher radiographic progression rate was observed in patients who received delayed versus immediate ADA + MTX treatment.

CONCLUSIONS: Longitudinal integrated analysis provided robust estimates of radiographic progression that only slightly differed from completers-only scores and confirmed the effects.

OriginalsprogEngelsk
TidsskriftArthritis Care & Research
Vol/bind67
Udgave nummer2
Sider (fra-til)180-6
Antal sider7
ISSN2151-464X
DOI
StatusUdgivet - feb. 2015

ID: 45080707